Opportunity: Danaher Corp.
Total Compensation Fund
$172.5 million
Period of Eligibility
2022 - 2024
Ticker
DHR
Deadline
TBD
Danaher Corporation is a multinational conglomerate headquartered in Washington, D.C., specializing in life sciences, diagnostics, environmental and applied solutions, and product identification. The company operates through multiple divisions, including its bioprocessing business that manufactures equipment for pharmaceutical and vaccine production. Danaher is known for its decentralized management structure and acquisition-driven growth strategy.
Danaher has deposited $172.5 to redress damages caused to investors between 2022 and 2024 following materially false and misleading statements about its bioprocessing business — the division that manufactures equipment for biopharmaceutical vaccine and therapeutic production.
The case centers on whether Danaher knowingly or recklessly misrepresented the health and trajectory of a strategically important business division, thereby deceiving investors about the company’s overall value and prospects.